Aurinia Pharmaceuticals Inc.
AUPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600620
In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 282 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Aurinia Pharmaceuticals Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 183 | 2 | 200 | +19 |
| Shares | 58.5M | 24.9K | 58.5M | −23.8K (0.0%) |
| Value | $428.9M | $182.6K | $525.4M | +$96.7M (+22.5%) |
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (38)
Institutions that held Aurinia Pharmaceuticals Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (19)
Institutions that held Aurinia Pharmaceuticals Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Rock Springs Capital Management LP | 1,179,740 | $8.65M |
| Wolverine Trading, LLC | 206,099 | $1.50M |
| Jump Financial, LLC | 189,955 | $1.39M |
| Algert Global LLC | 128,013 | $938.3K |
| GTS Securities LLC | 53,327 | $390.9K |
| Norges Bank | 35,532 | $260.4K |
| Teza Capital Management LLC | 28,452 | $208.6K |
| Sherbrooke Park Advisers LLC | 25,392 | $186.1K |
| EntryPoint Capital, LLC | 24,230 | $177.6K |
| Almanack Investment Partners, LLC. | 13,823 | $101.3K |
| Engineers Gate Manager LP | 10,520 | $77.1K |
| Acadian Asset Management LLC | 8,732 | $64.0K |
| Catalyst Funds Management Pty Ltd | 5,200 | $38.1K |
| nVerses Capital, LLC | 2,400 | $17.6K |
| Macquarie Group Ltd | 1,473 | $10.8K |
| Capital Performance Advisors LLP | 1,181 | $8.66K |
| Golden State Equity Partners | 900 | $6.60K |
| Zions Bancorporation, N.A. | 600 | $4.40K |
| Spectrum Wealth Counsel, LLC | 334 | $2.45K |
Not filed for Q4 2024 yet (2)
Institutions that held Aurinia Pharmaceuticals Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 15,225 | $111.6K |
| Banque Cantonale Vaudoise | 9,684 | $71.0K |